The Consortium works with international regulatory bodies and expert panels to develop and standardise in vitro nanotechnology testing strategies and pushes for the implementation of these non-animal approaches. In this capacity, the Consortium is a member of the US Technical Advisory Group to ISO/TC 229 Nanotechnologies and, through the International Council on Animal Protection in OECD Programmes, participates in the Organisation for Economic Co-operation and Development Working Party for Manufactured Nanomaterials. The Consortium also held a workshop on alternative methods for assessing the inhalation toxicity of nanomaterials in 2015 and subsequently funded the development of an in vitro system to predict the development of pulmonary fibrosis (see here).